Live Breaking News & Updates on A Us China Cross Border Biotech Company While At Kira Pharmaceuticals

SINGAPORE, BOSTON and SHANGHAI, June 28, 2022 /PRNewswire/ Cargene Biopharma Inc. ("Cargene", the "Company"), a biopharmaceutical company developing oligonucleotide therapeutics for liver and ophthalmic disorders, is excited to welcome Kathy He, a seasoned biopharmaceutical industry executive, to join the Company as Chief Executive Officer and a member of the board. Kathy brings over 20 years of R&D and commercial experience from multiple global companies to her new role at Cargene, notably in building differentiated product portfolios, developing strategic opportunities, and successfully bringing innovative therapeutics to market. Based in Singapore, Boston and Shanghai, Cargene Biopharma aims to leverage its novel biology and chemistry insights to develop highly specific, stable and potent nucleic acid therapeutics for a broad range of diseases. In December 2021, the Company successfully closed a pre-Series A funding round of nearly US$20 million, led by Bio ....

Kellogg School , United States , University Of Illinois , Cargene Biopharma , Head Of Corporate Development At Abbisko Therapeutics , Merck Co , Bayhelix Group , Wuhan University , Takeda Pharmaceuticals , Prior To Kira Pharmaceuticals , Kellogg School Of Management At Northwestern University , While At Kira Pharmaceuticals , Science Academy , Kira Pharmaceuticals , Abbott Labs , Prnewswire Cargene Biopharma Inc , University Of Illinois At Urbana Champaign , Chief Executive Officer , Yann Chong Tan , Chief Business Officer , General Manager , Corporate Development , Abbisko Therapeutics , Managing Director , Venture Partner , Molecular Biology ,